The Lancet Group ads

📢 Join our editors! Join The Lancet Surgery & Anaesthesiology's editorial team— Amy Slogrove, Editor-in-Chief, Callam Davidson, Deputy Editor, and Aimee Ramgolam, Senior Editor—for this Lancet Webinar dedicated to helping you publish with The Lancet Surgery & Anaesthesiology. During this webinar, you will: ✔️ Learn about the journal's aims and scope ✔️ Understand what our editors are looking for in a research paper ✔️ Gain practical tips for preparing your manuscript for submission to the journal Plus, ask our editors your questions during the Q&A session! Can't join us live? Don't worry, register now to watch live or to receive a link to the on-demand recording. 👉 Register today: http://spkl.io/60477TNV1 📆 Thurs, Dec 10, 2026 🕑 09:00 GMT / 10:00 CET

Guidelines have long favoured anti-staphylococcal penicillins for serious PSSA bacteraemia. Until now, no randomised trial had compared them with benzylpenicillin. The SNAP Trial Group did. Read the results, free in The Lancet.

First randomised trial: benzylpenicillin vs flucloxacillin or cloxacillin for PSSA bacteraemia. The SNAP Trial Group enrolled 281 adults across 67 hospitals in 8 countries. Read the results, free in The Lancet.

“Initially, quite a lot of researchers weren’t sure about our message that we might be able to prevent dementia,” says Prof Gill Livingston, Chair of the Lancet standing Commission on dementia prevention, intervention, and care. Nearly a decade on, the findings are shaping WHO guidelines and national policy worldwide. Find out more ⤵️

The clinical management of Alzheimer’s disease (AD) is entering a new era. In the last decade, the field of AD has seen transformative advances in epidemiology, treatment, prevention, and more. How do we maintain this momentum? In a Seminar, Alberto Serrano-Pozo & colleagues highlight the unmet needs and key priorities for future research. "Much more needs to be done, but this momentum is fuelling new avenues of research into Alzheimer’s disease that hold promise to flatten the trajectory of this devastating and complex neurodegenerative disease at both individual and societal levels", say the authors. Read now: http://spkl.io/60477THCT

Join leading voices in Sitges this November, including Chantal Mathieu, who will present on delaying the onset of type 1 diabetes.